Aktienanalyse zu Kodiak Sciences Inc (KOD)KODKodiak Sciences Inc

Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Kodiak Sciences Inc is currently trading at $37.72, which is significantly below the average analyst price target of $66 from JPMorgan, indicating potential upside. However, the RSI is at 32.96, suggesting it is oversold, and the company has reported consistent negative earnings, with a net income loss of $65.64 million in Q2 2026. The main risk is the ongoing negative earnings trend, with an EPS of -1.05 reported in the last quarter, which could affect investor sentiment.

1 analysts cover KOD: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 27.86.